What Is PMCF and Do I Really Need It? 4-Level Guide (2026)

Level 1 — Explain It Like I'm Five

Before you sell your toy car, you test it in your workshop. But after kids start playing with it in the real world — in rain, in sand, dropped from high places — you need to keep checking: is it still safe? Are the wheels still strong enough? Are kids using it in ways you didn't expect?

PMCF is that ongoing checking — Post-Market Clinical Follow-up. It means you keep gathering real-world evidence about how your medical device performs in actual patients, in actual hospitals, over actual years.

Level 2 — The General Picture

PMCF (Post-Market Clinical Follow-up) is a continuous process defined in EU MDR Annex XIV Part B that updates the clinical evaluation with real-world clinical data throughout the device's lifecycle.

Why does it exist?

Clinical investigations before CE marking are limited — small patient numbers, short follow-up, controlled conditions. PMCF fills the evidence gaps that remain after initial clinical evaluation, answering questions like: What is the device's long-term safety? Are there rare complications? How does it perform across diverse patient populations?

Is it mandatory?

Yes, for all device classes under the EU MDR. However, the scope scales with risk:

• Class III and implantables: Comprehensive PMCF with prospective data collection (registries, clinical studies) almost always expected
• Class IIa/IIb: PMCF required; methods may include literature reviews, registries, surveys
• Class I: PMCF required but may be justified as minimal scope (e.g., literature review only)

You can justify that no PMCF activities are needed — but the justification must be device-specific, risk-based, and convincing. Notified Bodies frequently challenge blanket "PMCF not applicable" statements.

Level 3 — How to Build a PMCF Program

Step 1: Write the PMCF Plan (use MDCG 2020-7 template)

Step 2: Execute PMCF activities

• Literature review: Systematic search (PubMed, Embase, Cochrane) per defined protocol. Not a one-time search — repeat at defined intervals.
• Registry participation: Enroll in disease-specific or device-specific registries where available (e.g., national arthroplasty registries for joint replacements).
• Surveys: Clinician and/or patient surveys collecting specific clinical outcomes.
• Proactive clinical studies: Prospective studies designed to answer PMCF clinical questions. Required for novel or high-risk devices.

Step 3: Write the PMCF Evaluation Report (use MDCG 2020-8 template)

The report must document: activities undertaken, data collected, analysis results, conclusions on safety and performance, and impact on the CER, risk management file, and labeling. It feeds directly into the PSUR.

What RA/QA needs to do

1. Identify clinical evidence gaps from the CER — these become PMCF questions
2. Select methods proportionate to device risk and evidence gaps
3. Define measurable endpoints and realistic timelines
4. Execute activities per the plan — track progress against milestones
5. Update the PMCF report when new data is available
6. Ensure PMCF findings flow into CER updates, PSUR, and risk file

Level 4 — The Deeper Analysis

The MDD-to-MDR evidence crisis

Under MDD, many devices were CE marked with limited clinical evidence — equivalence claims to predicate devices, literature reviews, and small case series. MDR raised the bar dramatically: equivalence requires documented technical, biological, and clinical equivalence with legal access to the equivalent device's technical file (Article 61(5)). For many legacy devices, this equivalence route is now closed. PMCF is the safety valve — the mechanism for building the clinical evidence that wasn't generated before initial certification.

Why "not applicable" rarely works

Notified Bodies have taken an increasingly strict stance on PMCF exemptions. Team-NB's 2025 Best Practice Guidance establishes strict evidence traceability: CER → PMCF Plan → PMCF Evaluation Report → PSUR → Risk Management File. A weak or absent PMCF plan triggers a high risk of major nonconformity. The only defensible "not applicable" justification is for well-established technology in Class I with extensive safety history and no residual clinical questions — and even then, literature monitoring as a PMCF activity is typically expected.

PMCF vs. FDA Section 522 studies

EU MDR PMCF is manufacturer-initiated and continuous. FDA Section 522 studies are FDA-ordered and targeted. Both serve the same purpose — generating real-world clinical data — but the triggering mechanisms differ. Under PMCF, the manufacturer proactively identifies and addresses evidence gaps. Under Section 522, FDA orders specific studies when it has unanswered safety/effectiveness questions (e.g., the metal-on-metal hip implant 522 orders in 2011). In practice, a robust PMCF program may prevent the need for a 522 order by proactively generating the data FDA would otherwise demand.